Loading...
•
Jun 30, 2020
Precigen Q2 2020 Earnings Report
Precigen's financial performance for Q2 2020 was announced, featuring a total revenue of $30.4 million and a net loss of $43.4 million.
Key Takeaways
Precigen reported a second-quarter revenue of $30.4 million and a net loss of $43.4 million, or $(0.26) per basic share. The company highlighted progress in clinical trials and the development of its UltraPorator manufacturing device.
Advanced the development of UltraPorator™ electroporation device, initiating cGMP manufacturing and technology transfer.
Initiated patient dosing in the third dose level of the Phase 1 clinical trial of PRGN-3005 UltraCAR-T for advanced ovarian cancer.
AG019 ActoBiotics™ Phase 1b monotherapy study met the primary endpoint for safety and tolerability in patients with early-onset type 1 diabetes.
INXN-4001 Phase I trial for heart failure met primary endpoints for safety and feasibility, with preliminary data suggesting improved patient outcomes.
Revenue by Segment
Forward Guidance
Precigen maintained its guidance for clinical readouts in 2020, anticipating additional results from clinical programs.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...